FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912403850> ?p ?o ?g. }

• W2912403850 endingPage "435" @default.
• W2912403850 startingPage "420" @default.
• W2912403850 abstract "Background VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether the addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. Methods For this double-blind, randomised, placebo-controlled, phase 3 trial done at 126 centres in 20 countries, we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function. Eligible patients were randomly assigned (1:1) with an interactive web response system to receive cisplatin (80 mg/m2, on the first day) plus capecitabine (1000 mg/m2, twice daily for 14 days), every 21 days, and either ramucirumab (8 mg/kg) or placebo on days 1 and 8, every 21 days. 5-Fluorouracil (800 mg/m2 intravenous infusion on days 1–5) was permitted in patients unable to take capecitabine. The primary endpoint was investigator-assessed progression-free survival, analysed by intention to treat in the first 508 patients. We did a sensitivity analysis of the primary endpoint, including a central review of CT scans. Overall survival was a key secondary endpoint. This study is registered with ClinicalTrials.gov, number NCT02314117. Findings Between Jan 28, 2015, and Sept 16, 2016, 645 patients were randomly assigned to receive ramucirumab plus fluoropyrimidine and cisplatin (n=326) or placebo plus fluoropyrimidine and cisplatin (n=319). Investigator-assessed progression-free survival was significantly longer in the ramucirumab group than the placebo group (hazard ratio [HR] 0·753, 95% CI 0·607–0·935, p=0·0106; median progression-free survival 5·7 months [5·5–6·5] vs 5·4 months [4·5–5·7]). A sensitivity analysis based on central independent review of the radiological images did not corroborate the investigator-assessed difference in progression-free survival (HR 0·961, 95% CI 0·768–1·203, p=0·74). There was no difference in overall survival between groups (0·962, 0·801–1·156, p=0·6757; median overall survival 11·2 months [9·9–11·9] in the ramucirumab group vs 10·7 months [9·5–11·9] in the placebo group). The most common grade 3–4 adverse events were neutropenia (85 [26%] of 323 patients in the ramucirumab group vs 85 [27%] of 315 in the placebo group), anaemia (39 [12%] vs 44 [14%]), and hypertension (32 [10%] vs 5 [2%]). The incidence of any-grade serious adverse events was 160 (50%) of 323 patients in the ramucirumab group and 149 (47%) of 315 patients in the placebo group. The most common serious adverse events were vomiting (14 [4%] in the ramucirumab group vs 21 [7%] in the placebo group) and diarrhoea (11 [3%] vs 19 [6%]). There were seven deaths in each group, either during study treatment or within 30 days of discontinuing study treatment, which were the result of treatment-related adverse events. In the ramucirumab group, these adverse events were acute kidney injury, cardiac arrest, gastric haemorrhage, peritonitis, pneumothorax, septic shock, and sudden death (n=1 of each). In the placebo group, these adverse events were cerebrovascular accident (n=1), multiple organ dysfunction syndrome (n=2), pulmonary embolism (n=2), sepsis (n=1), and small intestine perforation (n=1). Interpretation Although the primary analysis for progression-free survival was statistically significant, this outcome was not confirmed in a sensitivity analysis of progression-free survival by central independent review, and did not improve overall survival. Therefore, the addition of ramucirumab to cisplatin plus fluoropyrimidine chemotherapy is not recommended as first-line treatment for this patient population. Funding Eli Lilly and Company. VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to assess whether the addition of ramucirumab, a VEGFR-2 antagonist monoclonal antibody, to first-line chemotherapy improves outcomes in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma. For this double-blind, randomised, placebo-controlled, phase 3 trial done at 126 centres in 20 countries, we recruited patients aged 18 years or older with metastatic, HER2-negative gastric or gastro-oesophageal junction adenocarcinoma, an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, and adequate organ function. Eligible patients were randomly assigned (1:1) with an interactive web response system to receive cisplatin (80 mg/m2, on the first day) plus capecitabine (1000 mg/m2, twice daily for 14 days), every 21 days, and either ramucirumab (8 mg/kg) or placebo on days 1 and 8, every 21 days. 5-Fluorouracil (800 mg/m2 intravenous infusion on days 1–5) was permitted in patients unable to take capecitabine. The primary endpoint was investigator-assessed progression-free survival, analysed by intention to treat in the first 508 patients. We did a sensitivity analysis of the primary endpoint, including a central review of CT scans. Overall survival was a key secondary endpoint. This study is registered with ClinicalTrials.gov, number NCT02314117. Between Jan 28, 2015, and Sept 16, 2016, 645 patients were randomly assigned to receive ramucirumab plus fluoropyrimidine and cisplatin (n=326) or placebo plus fluoropyrimidine and cisplatin (n=319). Investigator-assessed progression-free survival was significantly longer in the ramucirumab group than the placebo group (hazard ratio [HR] 0·753, 95% CI 0·607–0·935, p=0·0106; median progression-free survival 5·7 months [5·5–6·5] vs 5·4 months [4·5–5·7]). A sensitivity analysis based on central independent review of the radiological images did not corroborate the investigator-assessed difference in progression-free survival (HR 0·961, 95% CI 0·768–1·203, p=0·74). There was no difference in overall survival between groups (0·962, 0·801–1·156, p=0·6757; median overall survival 11·2 months [9·9–11·9] in the ramucirumab group vs 10·7 months [9·5–11·9] in the placebo group). The most common grade 3–4 adverse events were neutropenia (85 [26%] of 323 patients in the ramucirumab group vs 85 [27%] of 315 in the placebo group), anaemia (39 [12%] vs 44 [14%]), and hypertension (32 [10%] vs 5 [2%]). The incidence of any-grade serious adverse events was 160 (50%) of 323 patients in the ramucirumab group and 149 (47%) of 315 patients in the placebo group. The most common serious adverse events were vomiting (14 [4%] in the ramucirumab group vs 21 [7%] in the placebo group) and diarrhoea (11 [3%] vs 19 [6%]). There were seven deaths in each group, either during study treatment or within 30 days of discontinuing study treatment, which were the result of treatment-related adverse events. In the ramucirumab group, these adverse events were acute kidney injury, cardiac arrest, gastric haemorrhage, peritonitis, pneumothorax, septic shock, and sudden death (n=1 of each). In the placebo group, these adverse events were cerebrovascular accident (n=1), multiple organ dysfunction syndrome (n=2), pulmonary embolism (n=2), sepsis (n=1), and small intestine perforation (n=1). Although the primary analysis for progression-free survival was statistically significant, this outcome was not confirmed in a sensitivity analysis of progression-free survival by central independent review, and did not improve overall survival. Therefore, the addition of ramucirumab to cisplatin plus fluoropyrimidine chemotherapy is not recommended as first-line treatment for this patient population." @default.
• W2912403850 created "2019-02-21" @default.
• W2912403850 creator A5000610387 @default.
• W2912403850 creator A5003239953 @default.
• W2912403850 creator A5003887338 @default.
• W2912403850 creator A5004167491 @default.
• W2912403850 creator A5005375804 @default.
• W2912403850 creator A5006313171 @default.
• W2912403850 creator A5007727137 @default.
• W2912403850 creator A5007730088 @default.
• W2912403850 creator A5009130863 @default.
• W2912403850 creator A5009523282 @default.
• W2912403850 creator A5010945467 @default.
• W2912403850 creator A5011450963 @default.
• W2912403850 creator A5011563007 @default.
• W2912403850 creator A5012034272 @default.
• W2912403850 creator A5012306007 @default.
• W2912403850 creator A5012310765 @default.
• W2912403850 creator A5012667192 @default.
• W2912403850 creator A5014027205 @default.
• W2912403850 creator A5015799240 @default.
• W2912403850 creator A5015937284 @default.
• W2912403850 creator A5016173075 @default.
• W2912403850 creator A5016708036 @default.
• W2912403850 creator A5017478217 @default.
• W2912403850 creator A5018246293 @default.
• W2912403850 creator A5019233587 @default.
• W2912403850 creator A5019353672 @default.
• W2912403850 creator A5019473289 @default.
• W2912403850 creator A5019680927 @default.
• W2912403850 creator A5020077097 @default.
• W2912403850 creator A5020105181 @default.
• W2912403850 creator A5020210648 @default.
• W2912403850 creator A5020227571 @default.
• W2912403850 creator A5021715818 @default.
• W2912403850 creator A5022364267 @default.
• W2912403850 creator A5022801937 @default.
• W2912403850 creator A5022916059 @default.
• W2912403850 creator A5023149954 @default.
• W2912403850 creator A5023215623 @default.
• W2912403850 creator A5023325144 @default.
• W2912403850 creator A5024085564 @default.
• W2912403850 creator A5024621925 @default.
• W2912403850 creator A5025120810 @default.
• W2912403850 creator A5025707844 @default.
• W2912403850 creator A5025857560 @default.
• W2912403850 creator A5025931905 @default.
• W2912403850 creator A5027192875 @default.
• W2912403850 creator A5027411414 @default.
• W2912403850 creator A5028472820 @default.
• W2912403850 creator A5028562022 @default.
• W2912403850 creator A5029612295 @default.
• W2912403850 creator A5031023319 @default.
• W2912403850 creator A5031466394 @default.
• W2912403850 creator A5031748554 @default.
• W2912403850 creator A5033420659 @default.
• W2912403850 creator A5033459242 @default.
• W2912403850 creator A5033985179 @default.
• W2912403850 creator A5034109602 @default.
• W2912403850 creator A5034600064 @default.
• W2912403850 creator A5035247062 @default.
• W2912403850 creator A5035278067 @default.
• W2912403850 creator A5035865205 @default.
• W2912403850 creator A5037607041 @default.
• W2912403850 creator A5038871065 @default.
• W2912403850 creator A5040676201 @default.
• W2912403850 creator A5042615950 @default.
• W2912403850 creator A5043104023 @default.
• W2912403850 creator A5045865889 @default.
• W2912403850 creator A5049314303 @default.
• W2912403850 creator A5049363884 @default.
• W2912403850 creator A5049658669 @default.
• W2912403850 creator A5049992875 @default.
• W2912403850 creator A5050098537 @default.
• W2912403850 creator A5050468802 @default.
• W2912403850 creator A5050481393 @default.
• W2912403850 creator A5050850130 @default.
• W2912403850 creator A5050914625 @default.
• W2912403850 creator A5051143027 @default.
• W2912403850 creator A5051327921 @default.
• W2912403850 creator A5051613962 @default.
• W2912403850 creator A5052177007 @default.
• W2912403850 creator A5052388939 @default.
• W2912403850 creator A5052643581 @default.
• W2912403850 creator A5053450523 @default.
• W2912403850 creator A5053589015 @default.
• W2912403850 creator A5053639618 @default.
• W2912403850 creator A5053820309 @default.
• W2912403850 creator A5054195758 @default.
• W2912403850 creator A5054786958 @default.
• W2912403850 creator A5055212193 @default.
• W2912403850 creator A5059283240 @default.
• W2912403850 creator A5060716896 @default.
• W2912403850 creator A5060759473 @default.
• W2912403850 creator A5061205710 @default.
• W2912403850 creator A5061594361 @default.
• W2912403850 creator A5062763170 @default.
• W2912403850 creator A5062868734 @default.

• next